Education
About Us
Working with TipRanks
Follow Us
Argenx (ARGX)
:ARGX
ARGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$352.77 - $678.21
Previous CloseN/A
Volume151.62K
Average Volume (3M)317.12K
Market Cap
$35.46B
Enterprise ValueN/A
Total Cash (Recent Filing)$39.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)40.8
Beta0.42
Next Earnings
May 08, 2025EPS Estimate
2.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.89
Shares Outstanding60,760,956
10 Day Avg. Volume300,520
30 Day Avg. Volume317,120
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)89.48
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$753.00Price Target Upside32.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
---
Argenx Se News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceVyvgart has been consistent beating estimates in gMG while the ongoing launch in CIDP is off to a terrific launch, also surpassing estimates.
Product DevelopmentThe possible approval of Vyvgart’s prefilled syringe formulation with potential self-administration is anticipated.
Regulatory ApprovalsVyvgart Hytrulo's pre-filled syringe received a positive CHMP opinion for generalized myasthenia gravis in Europe, marking the first positive regulatory decision globally.
Bears Say
Market CompetitionManagement is focused on collaborations rather than acquisitions, remaining committed to advancing new molecules into the clinic in the near-term.
---
Ownership Overview
―
Insiders
19.24% Mutual Funds
21.56% Other Institutional Investors
57.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARGX FAQ
What was Argenx’s price range in the past 12 months?
Argenx lowest stock price was $352.77 and its highest was $678.21 in the past 12 months.
What is Argenx’s market cap?
Argenx’s market cap is $35.46B.
When is Argenx’s upcoming earnings report date?
Argenx’s upcoming earnings report date is May 08, 2025 which is in 35 days.
How were Argenx’s earnings last quarter?
Argenx released its earnings results on Feb 27, 2025. The company reported $11.79 earnings per share for the quarter, beating the consensus estimate of $1.709 by $10.081.
Is Argenx overvalued?
According to Wall Street analysts Argenx’s price is currently Undervalued.
Does Argenx pay dividends?
Argenx does not currently pay dividends.
What is Argenx’s EPS estimate?
Argenx’s EPS estimate is 2.24.
How many shares outstanding does Argenx have?
Argenx has 60,760,956 shares outstanding.
What happened to Argenx’s price movement after its last earnings report?
Argenx reported an EPS of $11.79 in its last earnings report, beating expectations of $1.709. Following the earnings report the stock price went up 0.27%.
Which hedge fund is a major shareholder of Argenx?
Currently, no hedge funds are holding shares in ARGX
---
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$753.00 (32.78% Upside)
$753.00 (32.78% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 53.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.72%
12-Months-Change
Fundamentals
Return on Equity
17.33%
Trailing 12-Months
Asset Growth
36.55%
Trailing 12-Months
Company Description
Argenx
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
---
ARGX Company Deck
---
ARGX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical milestones, financial growth, and pipeline expansion, indicating strong momentum. However, there were challenges with exchange losses and an operating loss despite revenue growth. Overall, the positive aspects and future outlook outweigh the negatives.Read More>---
ARGX Stock 12 Month Forecast
Average Price Target
$753.00
▲(32.78% Upside)
Technical Analysis
Alnylam Pharma
―
Biogen
―
Regeneron
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering ARGX
1 Year
1 Year Success Rate
22/25 ratings generated profit
1 Year Average Return
+43.84%
reiterated a buy rating 21 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 88.00% of your transactions generating a profit, with an average return of +43.84% per trade.
---